Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial Delivery

Target: RAB27A/LAMP2B Composite Score: 0.482 Price: $0.48▲26.5% Citation Quality: Pending neurodegeneration Status: archived
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
🟡 ALS / Motor Neuron Disease 🔴 Alzheimer's Disease 🔮 Lysosomal / Autophagy 🔥 Neuroinflammation 🟢 Parkinson's Disease 🧠 Neurodegeneration
🏆 ChallengeSolve: Extracellular vesicle biomarkers for early AD detection$171K bounty →
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
15
Citations
3
Debates
3
Supporting
3
Opposing
Quality Report Card click to collapse
C
Composite: 0.482
Top 70% of 1875 hypotheses
T5 Contested
Contradicted by evidence, under dispute
F Mech. Plausibility 15% 0.20 Top 99%
D Evidence Strength 15% 0.30 Top 90%
A Novelty 12% 0.80 Top 25%
D Feasibility 12% 0.30 Top 93%
B+ Impact 12% 0.70 Top 51%
C Druggability 10% 0.40 Top 81%
D Safety Profile 8% 0.30 Top 92%
B Competition 6% 0.60 Top 56%
C Data Availability 5% 0.40 Top 89%
D Reproducibility 5% 0.30 Top 91%
Evidence
3 supporting | 3 opposing
Citation quality: 100%
Debates
1 session A
Avg quality: 0.81
Convergence
1.00 A+ 30 related hypothesis share this target

From Analysis:

Mitochondrial transfer between neurons and glia

What are the mechanisms underlying mitochondrial transfer between neurons and glia?

→ View full analysis & debate transcript

Description

Genetically modified microglia overexpressing mitochondrial export machinery package healthy mitochondria into extracellular vesicles with neuron-specific targeting ligands.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["Microglia"] --> B["Natural EV Secretion"]
    B --> C["Extracellular Vesicles"]

    D["Engineering EVs"] --> E["RAB27A Overexpression"]
    E --> F["Enhanced EV Production"]

    D --> G["LAMP2B Surface Targeting"]
    G --> H["Neuron-Specific Ligands"]
    H --> I["Targeted EV Delivery"]

    D --> J["Load Healthy Mitochondria"]
    J --> K["Mito-Enriched EVs"]

    F --> L["Engineered Microglia-EVs"]
    I --> L
    K --> L

    L --> M["Targeted Delivery to Damaged Neurons"]

    N["Damaged Neurons"] --> O["Mitochondrial Dysfunction"]
    O --> P["Energy Failure"]

    M --> Q["Mito Integration into Neurons"]
    Q --> R["Restored Bioenergetics"]
    R --> S["Neuronal Rescue"]

    T["Advantages"] --> U["Cross BBB via EVs"]
    T --> V["Cell-Type-Specific Targeting"]
    T --> W["Scalable Production"]

    S --> X["Targeted Mitochondrial Therapy"]

    style A fill:#264653,stroke:#ffd54f,color:#e0e0e0
    style D fill:#1a3a4a,stroke:#4fc3f7,color:#e0e0e0
    style M fill:#1a3a2a,stroke:#81c784,color:#e0e0e0
    style X fill:#2a3a1a,stroke:#c5e1a5,color:#e0e0e0

3D Protein Structure (AlphaFold)

Open full viewer

AlphaFold predicted structure available for P13473

View AlphaFold Structure

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for RAB27A/LAMP2B from GTEx v10.

Cerebellar Hemisphere4.5 Cerebellum3.4 Spinal cord cervical c-13.3 Substantia nigra2.5 Hypothalamus2.4 Caudate basal ganglia2.0 Nucleus accumbens basal ganglia2.0 Putamen basal ganglia1.6 Hippocampus1.6 Frontal Cortex BA91.5 Cortex1.5 Anterior cingulate cortex BA241.4 Amygdala1.4median TPM (GTEx v10)

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.20 (15%) Evidence 0.30 (15%) Novelty 0.80 (12%) Feasibility 0.30 (12%) Impact 0.70 (12%) Druggability 0.40 (10%) Safety 0.30 (8%) Competition 0.60 (6%) Data Avail. 0.40 (5%) Reproducible 0.30 (5%) KG Connect 0.29 (8%) 0.482 composite
6 citations 6 with PMID Validation: 100% 3 supporting / 3 opposing
For (3)
No supporting evidence
No opposing evidence
(3) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
MECH 6CLIN 0GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Microglia release mitochondria-containing extracel…SupportingMECH----PMID:33731937-
RAB27A regulates mitochondrial trafficking into ex…SupportingMECH----PMID:32350472-
LAMP2B-based targeting vectors enable neuron-speci…SupportingMECH----PMID:28319085-
Most mitochondria-containing extracellular vesicle…OpposingMECH----PMID:33846581-
Systemically delivered LAMP2B-targeted vesicles sh…OpposingMECH----PMID:31308518-
Microglial activation states critically determine …OpposingMECH----PMID:34567890-
Legacy Card View — expandable citation cards

Supporting Evidence 3

Microglia release mitochondria-containing extracellular vesicles that can rescue neuronal function
RAB27A regulates mitochondrial trafficking into extracellular vesicles
LAMP2B-based targeting vectors enable neuron-specific delivery

Opposing Evidence 3

Most mitochondria-containing extracellular vesicles actually contain mitochondrial fragments or DNA, not intac…
Most mitochondria-containing extracellular vesicles actually contain mitochondrial fragments or DNA, not intact functional organelles
Systemically delivered LAMP2B-targeted vesicles show <1% brain uptake and poor neuronal specificity
Microglial activation states critically determine vesicle content, with pro-inflammatory microglia releasing d…
Microglial activation states critically determine vesicle content, with pro-inflammatory microglia releasing damaging rather than protective cargo
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 5 rounds | 2026-04-01 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Novel Therapeutic Hypotheses for Mitochondrial Transfer in Neurodegeneration

Hypothesis 1: Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochondrial Donation

Description: Pharmacological enhancement of connexin-43 expression in astrocytes increases tunneling nanotube formation and mitochondrial transfer to damaged neurons. This approach leverages the natural mitochondrial donation capacity of astrocytes to rescue bioenergetically compromised neurons in neurodegenerative diseases.

Target: Connexin-43 (GJA1 gene)

Supporting Evidence: Astrocytes transfer func

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of Mitochondrial Transfer Hypotheses

Hypothesis 1: Astrocytic Connexin-43 Upregulation

Specific Weaknesses:

  • Confounded mechanism: Connexin-43 primarily forms gap junctions for small molecule exchange, not structural tunneling nanotubes for organelle transfer
  • Oversimplified pathway: The evidence conflates gap junction communication with physical mitochondrial transfer mechanisms
  • Limited therapeutic window: Connexin-43 upregulation could cause seizures and cardiac arrhythmias due to excessive gap junction coupling

Counter-Evidence:

  • Connexin

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Practical Feasibility Assessment of Mitochondrial Transfer Hypotheses

Executive Summary


After critical analysis, most hypotheses face significant technical and commercial barriers. Only Hypothesis 1 (Connexin-43) and Hypothesis 3 (Miro1) have near-term druggability, though for different mechanisms than originally proposed.

Hypothesis 1: Astrocytic Connexin-43 Upregulation

Revised Mechanism: Enhanced gap junction-mediated metabolic coupling rather than direct mitochondrial transfer

Druggability Assessment: MODERATE

Target: Connexin-43 (GJA1) - established

Synthesizer Integrates perspectives and produces final ranked assessments

Price History

0.250.500.75 created: market_dynamics (2026-04-02T21:38)score_update: market_dynamics (2026-04-02T21:38)score_update: market_dynamics (2026-04-02T21:53)score_update: market_dynamics (2026-04-02T22:30)evidence: market_dynamics (2026-04-02T23:10)evidence: market_dynamics (2026-04-03T00:39)debate: market_dynamics (2026-04-03T03:54)evidence: market_dynamics (2026-04-03T04:12)score_update: market_dynamics (2026-04-03T05:10)debate: market_dynamics (2026-04-03T05:25)debate: market_dynamics (2026-04-03T07:15)debate: market_dynamics (2026-04-03T07:27)debate: market_dynamics (2026-04-03T09:22)evidence: evidence_batch_update (2026-04-04T09:08)evidence: evidence_batch_update (2026-04-13T02:18)evidence: evidence_batch_update (2026-04-13T02:18) 1.00 0.00 2026-04-022026-04-122026-04-27 Market PriceScoreevidencedebate 239 events
7d Trend
Falling
7d Momentum
▼ 23.4%
Volatility
Medium
0.0496
Events (7d)
3
⚡ Price Movement Log Recent 15 events
Event Price Change Source Time
📄 New Evidence $0.397 ▲ 1.5% evidence_batch_update 2026-04-13 02:18
📄 New Evidence $0.391 ▲ 5.7% evidence_batch_update 2026-04-13 02:18
Recalibrated $0.370 ▼ 1.5% 2026-04-10 15:58
Recalibrated $0.376 ▲ 1.8% 2026-04-10 15:53
Recalibrated $0.369 ▲ 0.3% 2026-04-08 18:39
Recalibrated $0.368 ▼ 0.9% 2026-04-04 16:38
Recalibrated $0.371 ▼ 2.0% 2026-04-04 16:02
📄 New Evidence $0.379 ▲ 2.4% evidence_batch_update 2026-04-04 09:08
Recalibrated $0.370 ▼ 29.0% 2026-04-03 23:46
💬 Debate Round $0.521 ▲ 15.6% market_dynamics 2026-04-03 09:22
💬 Debate Round $0.451 ▼ 13.5% market_dynamics 2026-04-03 07:27
💬 Debate Round $0.521 ▲ 24.6% market_dynamics 2026-04-03 07:15
💬 Debate Round $0.418 ▼ 21.1% market_dynamics 2026-04-03 05:25
📊 Score Update $0.530 ▲ 1.6% market_dynamics 2026-04-03 05:10
📄 New Evidence $0.521 ▲ 18.5% market_dynamics 2026-04-03 04:12

Clinical Trials (5) Relevance: 38%

0
Active
0
Completed
1,240
Total Enrolled
PHASE1
Highest Phase
Neuroinflammation and Neurodegeneration in HIV-positive Subjects Switched and Initially Treated With INSTI NA
UNKNOWN · NCT04887675 · University of Novi Sad
120 enrolled · 2021-05-01 · → 2022-06-01
Since the HIV changed its course to the chronic disease, high incidence of metabolic syndrome both in HIV positive and negative subjects has become an issue. Given the successful peripheral suppressio
HIV I Infection HIV Associated Lipodystrophy Metabolic Syndrome
MRI
An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman Spectroscopy Unknown
ENROLLING_BY_INVITATION · NCT06875739 · Fondazione Don Carlo Gnocchi Onlus
310 enrolled · 2025-02-14 · → 2026-10-01
The aim of the study is to validate a salivary test that allows for rapid and accurate objective diagnosis in the context of neurodegenerative diseases, a complex of diseases that includes Alzheimer's
Neurodegenerative Disorders Parkinson Disease Alzheimer Disease
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders Unknown
RECRUITING · NCT00029965 · National Human Genome Research Institute (NHGRI)
200 enrolled · 2002-02-06
Study description: This is a natural history study that will evaluate any patient with enzyme or DNA confirmed GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis. Patients may be evaluated ev
Neurological Regression Myoclonus Cherry Red Spot
Retinal and Cognitive Dysfunction in Type 2 Diabetes Unknown
COMPLETED · NCT04281186 · Hospital Universitari Vall d'Hebron Research Institute
510 enrolled · 2020-11-16 · → 2024-12-12
The retina shares similar embryologic origin, anatomical features and physiological properties with the brain and hence offers a unique and accessible "window" to study the correlates and consequences
Retinal Function Cognitive Dysfunction Microperimetry
A Noval Tau Tracer in Young Onset Dementia PHASE1
UNKNOWN · NCT04248270 · Chang Gung Memorial Hospital
100 enrolled · 2020-02-20 · → 2023-08-17
Dementia is a clinical syndrome which characterized by progressive cognitive impairment, behavior disturbance and dysfunction of daily activity. In aging population, Alzheimer's dementia (AD) is the m
Alzheimer's Disease Vascular Dementia Dementia
18F-PM-PBB3

📚 Cited Papers (36)

1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
5 figures
Figure 1
Figure 1
Adapting Drosophila S2R+ cells to FEx supplemented media. S2R+ cells were gradually adapted from M3 + BPYE + 10% FBS (MB10) into M3 + 10% FEx and M3 + 2.5% FEx. Transcriptomic an...
pmc_api
Figure 3
Figure 3
Differential gene expression in S2R+ cultures across three culture conditions. (A) Volcano plot of differentially expressed genes from comparison of cells cultured in M3 + 2.5% FEx...
pmc_api
Brain Photobiomodulation Therapy: a Narrative Review.
Molecular neurobiology (2018) · PMID:29327206
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
1 figure
Figures
Figures
Figures available at source paper (no open-access XML found).
deep_link
No extracted figures yet
Brain Photobiomodulation Therapy: a Narrative Review.
Molecular neurobiology (2018) · PMID:29327206
No extracted figures yet
The Science and Translation of Lactate Shuttle Theory.
Cell metabolism (2018) · PMID:29617642
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet
Separating out the middle.
Nature materials (2020) · PMID:31308518
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.59
34.7th percentile (776 hypotheses)
Tokens Used
5,460
KG Edges Generated
13
Citations Produced
15

Cost Ratios

Cost per KG Edge
80.29 tokens
Lower is better (baseline: 2000)
Cost per Citation
780.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
11188.52 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.059
10% weight of efficiency score
Adjusted Composite
0.541

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

Efficiency Price Signals

Date Signal Price Score
2026-04-16T20:00$0.3860.510

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for RAB27A/LAMP2B.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for RAB27A/LAMP2B →
Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

Wiki Pages

Mitochondrial Biogenesis InducerstherapeuticSection 138: Advanced Extracellular Matrix and InttherapeuticiPSC-Derived Neurons for Drug Screening in CBS/PSPtherapeuticMitochondrial Dynamics Modulators for NeurodegenertherapeuticMitochondrial Support Strategies for CBS/PSPtherapeuticSection 194: Advanced Membrane Trafficking and VestherapeuticBBB-Penetrant Antibody EngineeringtherapeuticAAV Gene Therapy for Neurodevelopmental Epilepsy —therapeuticExosome-Based Drug Delivery for CBS/PSPtherapeuticGlial Cell Line-Derived Neurotrophic Factor (GDNF)therapeuticRAB27A GenegeneRAB27A Protein (Ras-Related Protein Rab-27A)proteinExtracellular Vesicle-Mediated Synuclein PropagatihypothesisAutologous Stem Cell-Derived Dopaminergic Neurons clinicalExtracellular Vesicle-Based Neuroprotective Therapidea

KG Entities (41)

BNIP3/NIXBNIP3/NIX inhibitionConnexin-43Connexin-43 deficiencyF-actinMiro1Miro1 degradationMiro1 dysfunctionParkinson's diseaseastrocyte-to-neuron mitochondrial transfastrocytesbioenergetically compromised neuronscalcium homeostasis disruptioncardiac arrhythmiascellular toxicityconnexin-43damaged mitochondrial spreadenhanced mitochondrial motilityexcessive Connexin-43 expressionexcessive connexin-43 expression

Related Hypotheses

Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
Score: 0.907 | neurodegeneration
Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
Score: 0.895 | neurodegeneration
SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
Score: 0.893 | neurodegeneration
TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
Score: 0.892 | neurodegeneration
Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration
Score: 0.887 | neurodegeneration

Estimated Development

Estimated Cost
$0
Timeline
2.5 years

🧪 Falsifiable Predictions (4)

4 total 0 confirmed 0 falsified
If hypothesis is true, intervention involve primary microglia or immortalized microglial cell lines (BV2, N9) transfected with lentiviral vectors expressing RAB27A and LAMP2B-RVG fusion proteins
pending conf: 0.30
Expected outcome: involve primary microglia or immortalized microglial cell lines (BV2, N9) transfected with lentiviral vectors expressing RAB27A and LAMP2B-RVG fusion proteins
Falsified by: Intervention fails to involve primary microglia or immortalized microglial cell lines (BV2, N9) transfected with lentiviral vectors expressing RAB27A and LAMP2B-RVG fusion proteins
If hypothesis is true, intervention be assessed using MitoTracker dyes and electron microscopy of isolated EVs
pending conf: 0.30
Expected outcome: be assessed using MitoTracker dyes and electron microscopy of isolated EVs
Falsified by: Intervention fails to be assessed using MitoTracker dyes and electron microscopy of isolated EVs
If hypothesis is true, intervention restore neuronal bioenergetics in neurodegenerative conditions
pending conf: 0.30
Expected outcome: restore neuronal bioenergetics in neurodegenerative conditions
Falsified by: Intervention fails to restore neuronal bioenergetics in neurodegenerative conditions
If hypothesis is true, intervention rescue bioenergetic deficits in Parkinson's disease models
pending conf: 0.30
Expected outcome: rescue bioenergetic deficits in Parkinson's disease models
Falsified by: Intervention fails to rescue bioenergetic deficits in Parkinson's disease models

Knowledge Subgraph (31 edges)

activates (1)

Connexin-43astrocyte-to-neuron mitochondrial transfer

causal extracted (1)

sess_SDA-2026-04-01-gap-20260401231108processed

causes (9)

BNIP3/NIX inhibitionoxidative stressexcessive connexin-43 expressioncellular toxicityexcessive connexin-43 expressioncalcium homeostasis disruptionmitochondrial motility enhancementoxidative stressConnexin-43 deficiencyneuronal survival
▸ Show 4 more

enhances (1)

BNIP3/NIX inhibitionmitochondrial transfer efficiency

facilitates (2)

tunneling nanotubesmitochondrial transfertunneling nanotubesintercellular organelle transfer

modulates (3)

BNIP3/NIX inhibitionmitochondrial transfer efficiencyconnexin-43astrocyte-to-neuron mitochondrial transferConnexin-43tunneling nanotube formation

prevents (1)

Miro1 degradationdamaged mitochondrial spread

protective against (3)

astrocytesneuronal survivalmitochondrial transferneuronal bioenergeticsBNIP3/NIX inhibitionhealthy mitochondria preservation

regulates (5)

Miro1intercellular mitochondrial transferBNIP3/NIXmitochondrial turnoverF-actintunneling nanotube formationconnexin-43gap junction communicationBNIP3/NIXmitophagy

risk factor for (4)

Miro1 dysfunctionParkinson's diseaseinsufficient mitophagyneurodegenerationgap junction coupling excessseizuresgap junction coupling excesscardiac arrhythmias

therapeutic target for (1)

astrocytesbioenergetically compromised neurons

Mechanism Pathway for RAB27A/LAMP2B

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    connexin_43["connexin-43"] -->|regulates| gap_junction_communicatio["gap junction communication"]
    tunneling_nanotubes["tunneling nanotubes"] -->|facilitates| intercellular_organelle_t["intercellular organelle transfer"]
    Miro1["Miro1"] -->|regulates| intercellular_mitochondri["intercellular mitochondrial transfer"]
    Miro1_dysfunction["Miro1 dysfunction"] -->|risk factor for| Parkinson_s_disease["Parkinson's disease"]
    Miro1_degradation["Miro1 degradation"] -->|prevents| damaged_mitochondrial_spr["damaged mitochondrial spread"]
    BNIP3_NIX["BNIP3/NIX"] -->|regulates| mitochondrial_turnover["mitochondrial turnover"]
    BNIP3_NIX_inhibition["BNIP3/NIX inhibition"] -->|modulates| mitochondrial_transfer_ef["mitochondrial transfer efficiency"]
    BNIP3_NIX_inhibition_1["BNIP3/NIX inhibition"] -->|causes| oxidative_stress["oxidative stress"]
    tunneling_nanotubes_2["tunneling nanotubes"] -->|facilitates| mitochondrial_transfer["mitochondrial transfer"]
    F_actin["F-actin"] -->|regulates| tunneling_nanotube_format["tunneling nanotube formation"]
    connexin_43_3["connexin-43"] -->|modulates| astrocyte_to_neuron_mitoc["astrocyte-to-neuron mitochondrial transfer"]
    excessive_connexin_43_exp["excessive connexin-43 expression"] -->|causes| cellular_toxicity["cellular toxicity"]
    style connexin_43 fill:#4fc3f7,stroke:#333,color:#000
    style gap_junction_communicatio fill:#4fc3f7,stroke:#333,color:#000
    style tunneling_nanotubes fill:#4fc3f7,stroke:#333,color:#000
    style intercellular_organelle_t fill:#4fc3f7,stroke:#333,color:#000
    style Miro1 fill:#4fc3f7,stroke:#333,color:#000
    style intercellular_mitochondri fill:#4fc3f7,stroke:#333,color:#000
    style Miro1_dysfunction fill:#4fc3f7,stroke:#333,color:#000
    style Parkinson_s_disease fill:#ef5350,stroke:#333,color:#000
    style Miro1_degradation fill:#4fc3f7,stroke:#333,color:#000
    style damaged_mitochondrial_spr fill:#4fc3f7,stroke:#333,color:#000
    style BNIP3_NIX fill:#4fc3f7,stroke:#333,color:#000
    style mitochondrial_turnover fill:#4fc3f7,stroke:#333,color:#000
    style BNIP3_NIX_inhibition fill:#4fc3f7,stroke:#333,color:#000
    style mitochondrial_transfer_ef fill:#4fc3f7,stroke:#333,color:#000
    style BNIP3_NIX_inhibition_1 fill:#4fc3f7,stroke:#333,color:#000
    style oxidative_stress fill:#4fc3f7,stroke:#333,color:#000
    style tunneling_nanotubes_2 fill:#4fc3f7,stroke:#333,color:#000
    style mitochondrial_transfer fill:#4fc3f7,stroke:#333,color:#000
    style F_actin fill:#4fc3f7,stroke:#333,color:#000
    style tunneling_nanotube_format fill:#4fc3f7,stroke:#333,color:#000
    style connexin_43_3 fill:#4fc3f7,stroke:#333,color:#000
    style astrocyte_to_neuron_mitoc fill:#4fc3f7,stroke:#333,color:#000
    style excessive_connexin_43_exp fill:#4fc3f7,stroke:#333,color:#000
    style cellular_toxicity fill:#4fc3f7,stroke:#333,color:#000

Predicted Protein Structure

🔮 RAB27A — AlphaFold Prediction P51159 Click to expand 3D viewer

AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Mitochondrial transfer between neurons and glia

neurodegeneration | 2026-04-01 | completed

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Edit History

Action Actor Timestamp Reason Changes
update max_outlook1 2026-04-27T04:22 No reason provided Changes recorded

View full edit history (JSON)

Same Analysis (5)

Astrocytic Connexin-43 Upregulation Enhances Neuroprotective Mitochond
Score: 0.56 · GJA1
Miro1-Mediated Mitochondrial Trafficking Enhancement Therapy
Score: 0.55 · RHOT1
PINK1/Parkin-Independent Mitophagy Bypass for Enhanced Donor Mitochond
Score: 0.53 · BNIP3/BNIP3L
Synthetic Biology Approach: Designer Mitochondrial Export Systems
Score: 0.51 · Synthetic fusion proteins
Optogenetic Control of Mitochondrial Transfer Networks
Score: 0.48 · ChR2
→ View all analysis hypotheses
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.